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1114Objective: Hypothermic cardiopulmonary bypass (CPB), although associated with a reduction in oxygen re-
quirement, has a number of disadvantages including detrimental effects on enzymatic function, energy gener-
ation, and cellular integrity. Normothermic perfusion is potentially a more physiologic method to maintain
the functional integrity of major organ systems. One of the aims of this trial was to compare the effect of nor-
mothermic and hypothermic CPB on renal injury in pediatric patients undergoing cardiac surgery.
Methods: Fifty-nine children (median age, 78 months; interquartile range, 39–130) undergoing corrective car-
diac surgery were randomized to either hypothermic (28C) or normothermic (35C-37C) CPB. Urinary albu-
min, retinal binding protein (RBP) and N-acetyl-b-glucosaminidase (NAG) were measured preoperatively, end
of CPB, 4, and 24 hours postoperatively and were expressed as a ratio of urinary creatinine. Serum creatininewas
measured preoperatively, end of CPB, and 24 and 48 hours postoperatively. Results are expressed as a difference
in means (normotherichypothermic) or as a ratio of geometric means (normothermic/hypothermic).
Results: Baseline characteristics were similar in both groups. For these biochemical markers no significant in-
teractions between treatment and postintervention time were found. Serum creatinine (2.10; 95% confidence
interval [CI],6.51-2.31), RBP (ratio, 0.96; 95% CI, 0.65-1.41), and NAG (ratio, 0.86; 95%CI, 0.56-1.36) were
similar in the 2 groups (P  .34), but the urinary albumin was significantly lower in the normothermic group
(ratio, 0.63; 95% CI, 0.42-0.95, P ¼ .03).
Conclusions: Normothermic CPB is associated with similar renal impairment to hypothermic CPB in children
undergoing heart surgery. (J Thorac Cardiovasc Surg 2011;142:1114-21)Supplemental material is available online.Earn CME credits at
http://cme.ctsnetjournals.org
Themain rationale for body cooling during cardiopulmonary
bypass (CPB) is to protect organs such as the brain, the kid-
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The Journal of Thoracic and Cardiovascular Surmetabolic rate and oxygen consumption1 and decreasing
the whole-body inflammatory response.2-4 However, the
combined effects of hypothermia, nonpulsatile perfusion,
and reduced mean arterial pressure cause release of
angiotensin, renin, catecholamines, and antidiuretic
hormones.5 These circulating hormones promote renal vaso-
constriction, reduce total renal blood flow, and redistribute
intrarenal bloodflow to the renalmedulla.Also, organ imma-
turity can result in a reduced glomerular filtration rate and
medullary concentration ability.5 The limited uncontrolled
clinical data available suggest that the risks of renal failure
associated with normothermic and hypothermic CPB are
comparable.6 Ip-Yam and associates7 demonstrated no dif-
ference in creatinine clearance, fractional sodium excretion,
microalbuminuria, and urinary N-acetyl-b-D-glucosamini-
dase (NAG) after normothermic (37C) versus hypothermic
(28C) CPB. In a randomized controlled trial in adults, our
group8 demonstrated that CPB perfusion temperature does
not influence perioperative changes in serum markers of re-
nal function and that normothermic CPB was not associated
with an increased risk of postoperative renal failure.
CPB perfusion temperature strategies and their effects on
organ function are largely the result of work carried out in
adult humans6-9 or in animal models,2,3 and the
conclusions drawn from those studies cannot necessarily
be applied directly to infants or children. In a randomizedgery c November 2011
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CI ¼ confidence interval
CPB ¼ cardiopulmonary bypass
ICU ¼ intensive care unit
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Dcontrolled trial in infants and children undergoing cardiac
surgery, we9 recently demonstrated that normothermic
CPB was associated with reduced oxidative stress and sim-
ilar myocardial reperfusion injury and inflammatory re-
sponse compared with hypothermic CPB. In this report,
from the same trial, we compare the effect of normothermic
and hypothermic CPB on renal injury in children undergo-
ing repair of simple congenital cardiac malformations.
PATIENTS AND METHODS
Fifty-nine children undergoing corrective cardiac surgery between Au-
gust 2002 and September 2004 at the Bristol Royal Hospital for Children
were randomized to receive either hypothermic (28C) or normothermic
(35C-37C) CPB. Neonates or patients requiring hypothermic circulatory
arrest or complex repair of the pulmonary arterial system with periods of
low-flow CPB were excluded from the study, as were patients with pre-
existing renal dysfunction. The study was approved by the Bristol Royal
Hospital Ethical Committee and parental informed consent was gained
for all patients. Random treatment allocations were generated by computer
in advance of starting the study, using block randomization with varying
block sizes. Allocation details were concealed in sequentially numbered,
opaque sealed envelopes. Randomization was revealed to the surgeon after
the start of the operation.
Anesthetic and Surgical Technique
Anesthetic techniquewas standardized as reported previously.9 Temper-
ature was monitored via nasopharyngeal, rectal, and skin probes. On estab-
lishment of CPB, the patient was either cooled to a target nasopharyngeal
temperature of 28C or maintained at 35C to 37C depending on random-
ization. Cold blood (4C-6C) St Thomas’ Hospital I–based cardioplegic
solution (4:1 dilution blood/St Thomas’ Hospital I crystalloid cardioplegic
solution) was used for myocardial preservation, with the following compo-
sition (in millimoles per liter): 16 MgCl2, 2 CaCl2, 20 KCl, 147 NaCl, and
1.0 procaine HCl. Additional cardioplegic solution was administered after
each 20 minutes of aortic crossclamping. CPB flow was kept between 3.0
and 3.5 L m2 min1, and hematocrit values were maintained between 25%
and 30%. In the hypothermic group, rewarming was started just before re-
moval of the aortic crossclamp. Patients were rewarmed with a temperature
difference of 8C at the level of the heat exchanger between the blood and
the rewarming fluid. Rewarming took place in the normothermic group
only if the temperature was less than 36C. A dopamine infusion was com-
menced in all patients at an initial rate of 5 mg $ kg1 $min1 beforeweaning
from CPB. Patients were weaned from CPB once the nasopharyngeal tem-
perature had reached 36C.
After the operation, all patients were admitted to the pediatric intensive
care unit (ICU) and were managed according to the unit protocols9 by in-
tensivists and pediatric cardiologists blinded to the randomization.
Outcome Variables
End points were the release of urinary albumin, retinal binding protein
(RBP), and NAG measured preoperatively, at the end of CPB, and 4 andThe Journal of Thoracic and Car24 hours postoperatively. All urinary markers were also expressed as a ra-
tio of urinary creatinine to adjust for variations in the glomerular filtration
rate. Serum urea, creatinine, and electrolytes were measured preopera-
tively, at the end of CPB, and 24, 48, and 72 hours postoperatively. Serum
levels of glucose, lactate, and hematocrit were also measured preopera-
tively, intraoperatively, and up to 24 hours postoperatively. We also re-
corded all-cause in-hospital mortality and morbidity as previously
reported.9
Study Size
The study sample size for the trial was set at 29 patients per group.
This sample size was based on our previous experience in similar stud-
ies on adult and pediatric patients4,9,10 in which we have been able to
demonstrate differences for the total area under curves describing the
levels of biochemical markers during the first 24 hours after surgery
as 0.8 to 1.1 standard deviations. A study with 29 patients per group
is sufficient to detect a difference between groups equivalent to 0.75
standard deviations (ie, about the minimum observed in our previous
studies) or greater with 80% power at a 5% significance level (2-
tailed).
Sample Collection and Analysis
The urine samples were centrifuged at 1000 g for 5 minutes and the
supernatants were stored at 20C. Biomarkers were measured within
2 weeks after initial urine collection. Urinary NAG was measured by col-
orimetric assay by using a commercially available kit (Roche Applied Sci-
ence, Indianapolis, Ind)11 according to the manufacturer’s protocol.
Urinary RBP was analyzed using a very sensitive latex-enhanced immuno-
assay techniquewith nephelometric detection.12 Urinary albumin wasmea-
sured using a turbimetric assay. The measured values were normalized to
the urinary creatinine concentration. The measurements were made in du-
plicate and in a blinded fashion.
Serum and urine creatinine concentrations were measured by the Jaffe
assay using Roche/Hitachi 917 systems (Roche Diagnostics, Indianapolis,
Ind) and Creatinine Companion (Exocell, Philadelphia, Pa),13 respectively.
Statistical Analysis
Analyses were carried out on the basis of intention to treat. Continuous
variables were summarized using the mean and standard deviation (or me-
dian and interquartile range if the distribution was skewed), and categorical
data were summarized as a number and percentage. Crossclamp and CPB
times were compared using the Wilcoxon rank sum test.
Continuous biomarker outcomes are compared between the hypother-
mic and normothermic CPB groups using a difference in means, with log-
arithmic transformations if distributions were skewed. For transformed
data the results are transformed back to the original scale after analysis,
with the treatment effect expressed as a ratio of geometric means. Repeated
measures of continuous outcomes were analyzed using the linear mixed ef-
fects methodology, and the preoperative and postoperative values were
modeled jointly to avoid the need to exclude or impute values for cases
with missing preoperative values. Treatment by time interactions was ex-
amined and if the interaction was statistically significant at the 10% level
using a likelihood ratio test, changes in treatment effect with time are de-
scribed; otherwise, an overall treatment effect (pooled over the postinter-
vention time points measured) is reported. The validity of the models
fitted was assessed graphically.
Results are presented as effect sizes with 95% confidence intervals (CI).
No correction has been made for multiple comparisons, but our interpreta-
tion of the findings takes into account the consistency of the associations
observed and their magnitude, as well as their statistical significance.
Mixed models were fitted in SAS version 9.2 (SAS Institute, Inc, Cary,
NC). All other analyses were performed using Stata version 11.1 (Stata-
Corp LP, College Station, Tex).diovascular Surgery c Volume 142, Number 5 1115
TABLE 1. Baseline characteristics
Hypothermic
CPB (n ¼ 31)
Normothermic
CPB (n ¼ 28)
Median
or n IQR or%
Median
or n IQR or%
Age (mo) 52 26-138 90.5 42-127
Male gender 16 52 9 32
Cyanotic 2 6 1 4
Indication
ASD 10 32 12 43
VSD 12 39 9 36
AV valve repair 2 6 1 4
pAVSD 4 13 1 4
RVOT repair 3 10 0 0
PA reconstruction 1 3 1 4
Pulmonary valvotomy 0 0 1 4
PAPVD 0 0 1 4
SubAS 5 16 3 11
PVR 1 3 0 0
TVR 1 3 0 0
AoV repair 1 3 0 0
Redo 4 13 5 18
Body surface area (m2) 0.69 0.50-1.2 0.90 0.65-1.12
Data are number and percentage or median and interquartile range (IQR). CPB, Car-
diopulmonary bypass; ASD, atrial septal defect; VSD, ventricular septal defect; AV,
atrioventricular; pAVSD, atrioventricular septal defect; RVOT, right ventricular out-
flow tract; PA, pulmonary artery; PAPVD, partial anomalous pulmonary venous
drainage; AS, aortic stenosis; PVR, pulmonary valve repair; TVR, tricuspid valve re-
pair; AoV, aortic valve.
TABLE 2. Operative characteristics and clinical outcomes
Hypothermic
CPB (n ¼ 31)
Normothermic
CPB (n ¼ 28)
Median
or n
IQR or
%
Median
or n
IQR or
%
Crossclamp time (min) 32 27-49 22 14.5-33
CPB time (min) 62.0 47-79 48.5 39-66
Lowest body temperature (C) 28.2 28.0-28.6 35.0 34.9-35.5
In-hospital mortality 0 0
Blood loss first 24 h (mL) 130 95-240 160 127.5-267.5
Fluid balance (mL) þ46 280-143 þ34.75 262.5-139
Red cell transfusion (mL/kg) 8 29 8 29
9.5 6.8-16.6 9.6 6.8-19.7
Platelet/FFP transfusion
(mL/kg)
5 18 6 21
5.2 4.9-5.5 9.9 4.9-10.0
Inotropic support 24 77 17 61
Total (mg kg1 min1) 18.2 11.8-38.3 15.0 10.0-20.5
Peak (mg kg1 min1) 6.5 5-10 5.0 5-10
Duration (h) 20 14.5-24 19 12-22
Diuretic use 4 13 1 4
Postoperative ventilation
time (h)
8 6-23 8.5 6-21
Postoperative hospital stay (d) 5 5-7 5 5-6
Data are number and percentage or median and interquartile range (IQR). CPB, Car-
diopulmonary bypass; FFP, fresh frozen plasma.
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DRESULTS
Thirty one patients were randomized to the hypothermic
group and 28 to the normothermic group. Overall, the me-
dian age was 78 months (interquartile range, 39-130) with
42% male. Reasons for surgery included a predominance
of atrial (37%) and ventricular septal defects (33%).
There were 9 redo procedures (Table 1). As anticipated,
lowest body and reperfusion temperatures were both sig-
nificantly lower in the hypothermic group (both
P< .0001). Operative and clinical outcomes are reported
in Table 2. Mortality and morbidity were similar across
the 2 groups, as was the use of diuretics. Crossclamp
and CPB times were lower in the normothermic group
(P ¼ .001 and P ¼ .03, respectively).
Urinary albumin, RBP, and NAGwere released in a time-
dependent fashion (Table 3). Urinary albumin concentration
decreased after 4 and 24 hours from the end of CPB, and
there was an increase of RBP and NAG levels over postin-
tervention time in both groups, but there was no evidence to
suggest time-related differences between the 2 groups when
expressed as a ratio of urinary creatinine (test for time by
treatment interaction, P  .46).
When the levels are expressed as a ratio of urinary creat-
inine, the urinary albumin was, on average, 37% lower in
the normothermic group (ratio, 0.63; 95% CI, 0.42-0.95;
P ¼ .03; Figure 1). In contrast, RBP was similar across1116 The Journal of Thoracic and Cardiovascular Surthe 2 groups (ratio, 0.96; 95% CI, 0.65-1.41; P ¼ .8;
Figure 2). NAG was, on average 14% lower (ratio, 0.86;
95% CI, 0.56-1.36; P ¼ .5; Figure 3), but this difference
was not significantly significant. With the exception of the
urinary albumin/creatinine ratio, none of the differences
was statistically significant (Figure 4).
Postoperative serum glucose, hematocrit, creatinine,
urea, and electrolytes were, on average, lower in the nor-
mothermic group, but the differences observed between
the 2 groups were not statistically significant (P  .07;
Appendix E1). The serum creatinine and urea were re-
duced by 2.1 mmol/L (95% CI, 6.51 to 2.31; P ¼ .34)
and 0.42 mmol/L (95% CI,0.88 to 0.04; P ¼ .072), on
average, respectively.
DISCUSSION
To the best of our knowledge, this is the first randomized
trial to compare the effects of hypothermic and normother-
mic CPB on renal function in pediatric heart surgery. Our
results suggest that, overall, normothermic CPB is associ-
ated with similar postoperative renal injury compared
with hypothermic CPB. Both normothermia and hypother-
mia resulted in a significant release of urinary markers of
kidney injury, with NAG and RBP levels remaining elevated
up to 24 hours postoperatively. These markers are sensitive
and reliable indicators of renal tubular injury early after car-
diac surgery compared with conventional parameters such
as blood urea and serum creatinine.14-16gery c November 2011
TABLE 3. Biochemical markers
Hypothermic
CPB (n ¼ 31)
Normothermic
CPB (n ¼ 28)
Difference
(normothermic
hypothermic)
Ratio*
(normothermic/
hypothermic) P valueMean SE Mean SE
Protein (logarithmic scale)
Baseline (mean, SD) 2.28 0.61 2.14 0.71
End of CPB 2.42 0.16 2.16 0.17 þ0.26 1.30
End of CPBþ4 h 2.23 0.11 2.52 0.12 0.29 0.75
End of CPBþ24 h 2.04 0.13 2.29 0.13 0.25 0.78
Test for interaction between treatment and time .18
Overall treatment effecty 0.09 (0.30 to 0.11) 0.91 (0.74 to 1.12) .38
Albumin (logarithmic scale)
Baseline (mean, SD) 3.04 0.77 3.45 0.90
End of CPB 3.25 0.25 3.21 0.27 0.04 0.96
End of CPBþ4 h 2.95 0.18 2.75 0.19 0.19 0.82
End of CPBþ24 h 2.89 0.15 2.73 0.15 0.17 0.85
Test for interaction between treatment and time .91
Overall treatment effecty 0.13 (0.50 to 0.23) 0.87 (0.61 to 1.26) .47
RBP (logarithmic scale)
Baseline (mean, SD) 4.00 2.16 3.89 1.94
End of CPB 2.91 0.24 3.48 0.27 þ0.57 (-0.15 to 1.28) 1.77 (0.86 to 3.61) .12
End of CPBþ4 h 4.78 0.27 4.21 0.28 0.57 (1.15 to 0.02) 0.57 (0.32 to 1.02) .056
End of CPBþ24 h 4.49 0.26 4.25 0.27 0.24 (0.69 to 0.22) 0.79 (0.50 to 1.25) .30
Test for interaction between treatment and time .032
NAG (logarithmic scale)
Baseline (mean, SD) 1.47 1.00 1.63 1.30
End of CPB 1.79 0.22 1.96 0.24 þ0.17 1.19
End of CPBþ4 h 2.33 0.19 2.09 0.20 0.24 0.79
End of CPBþ24 h 2.26 0.20 2.20 0.21 0.05 0.95
Test for interaction between treatment and time .51
Overall treatment effecty 0.04 (0.45 to 0.37) 0.96 (0.64 to 1.45) .85
RBP: creatinine ratio (logarithmic scale)
Baseline (mean, SD) 3.257 1.687 2.596 1.973
End of CPB 1.606 0.228 1.765 0.242 þ0.159 1.17
End of CPBþ4 h 4.080 0.269 3.879 0.286 0.201 0.82
End of CPBþ24 h 3.315 0.246 3.220 0.246 0.095 0.91
Test for interaction between treatment and time .65
Overall treatment effecty 0.046 (0.434 to 0.342) 0.96 (0.65 to 1.41) .81
Albumin: creatinine ratio (logarithmic scale)
Baseline (mean, SD) 1.91 0.72 2.17 0.98
End of CPB 1.80 0.32 1.24 0.33 0.55 0.58
End of CPBþ4 h 2.61 0.16 2.14 0.17 0.47 0.62
End of CPBþ24 h 1.93 0.17 1.56 0.16 0.36 0.70
Test for interaction between treatment and time .88
Overall treatment effecty 0.46 (0.87 to0.05) 0.63 (0.42 to 0.95) .028
NAG: creatinine ratio (logarithmic scale)
Baseline (mean, SD) 0.31 0.88 0.18 1.19
End of CPB 0.29 0.23 0.38 0.25 0.09 1.09
End of CPBþ4 h 1.82 0.22 1.45 0.23 0.37 0.69
End of CPBþ24 h 1.05 0.19 1.17 0.19 0.12 0.89
Test for interaction between treatment and time .463
Overall treatment effecty 0.13 (0.58 to 0.31) 0.86 (0.56 to 1.36) .55
CPB, Cardiopulmonary bypass; SE, standard error; SD, standard deviation; RBP, retinal binding protein; NAG, N-acetyl-b-D-glucosaminidase. *Ratio of geometric means for
skewed measures analyzed on the logarithmic scale. yDifference between the groups pooled over the postintervention time points as there was no evidence to suggest the dif-
ference varied across the time points studied.
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FIGURE 1. Time-related urinary changes in the albumin/creatinine in the
hypothermic (—) and normothermic (- - -) groups. CPB, Cardiopulmonary
bypass.
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Time post end of CPB (hours)
Hypothermic Normothermic
FIGURE 3. Time-related urinary changes in the NAG/creatinine in the
hypothermic (—) and normothermic (- - -) groups. CPB, Cardiopulmonary
bypass; NAG, N-acetyl-b-D-glucosaminidase.
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DIn the normothermic group, we observed a trend toward
lower levels of NAG and albumin (14% and37%, respec-
tively) when expressed as a urinary creatinine ratio as well
as lower serum creatinine and urea concentrations com-
pared with the hypothermic group (Table 3 and Appendix
E1). With the exception of albumin, these differences did
not reach statistical significance but might indicate a degree
of organ injury that is exacerbated by the cooling and re-
warming process in the hypothermic group. Boodhwani
and associates17 recently demonstrated that rewarming
from mild hypothermia and the longer CPB time were pre-
dictors of renal dysfunction in adults undergoing coronary
artery bypass grafting. Similar findings were reported by
Kourliouros and colleagues,18 who identified reduced arte-
rial perfusion temperature as an independent risk factor for
renal injury in patients undergoing coronary artery bypass
grafting. Animal studies17 have suggested that the kidney,5
10
20
40
60
80
Baseline 4 24
Time post end of CPB (hours)
Hypothermic Normothermic
FIGURE 2. Time-related urinary changes in the RBP/creatinine in the hy-
pothermic (—) and normothermic (- - -) groups. CPB, Cardiopulmonary
bypass; RBP, retinal binding protein.
1118 The Journal of Thoracic and Cardiovascular Surwith its high perfusion, rewarms even more rapidly than
the brain, and renal temperatures likely exceed the temper-
atures monitored clinically during rewarming, causing a hy-
perthermia-induced exacerbation of injury. It is also
interesting to note that other studies have demonstrated
a higher incidence of neurocognitive deficits19 and myocar-
dial reoxegenation injury in patients rewarmed from hypo-
thermic CPB.10
The protective effects of hypothermia on organ function
in the setting of ischemic injury have been previously
demonstrated in animal models. In rodent models of renal
ischemia and reperfusion, hyperthermia is associated with
increased renal injury whereas hypothermia is protec-
tive.20,21 In the adult clinical setting, however, the
benefits of hypothermia remain debated. SwaminathanFIGURE 4. Treatment effects pooled over time. Treatment effect not shown
for RBP as the effect varied with time (P¼ 0.32) Baseline and postinterven-
tion measures were modelled jointly on the logarithmic measurement scale.
RBP, Retinal binding protein; NAG, N-acetyl-b-D-glucosaminidase.
gery c November 2011
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Dand colleagues22 examined the effects of warm (35.5C-
36.5C) versus cold (28C–30C) CPB management and
found no difference in renal outcome between patient
groups. Our group8 reported the results of a randomized
trial that evaluated 3 temperature management protocols
in adult patients undergoing myocardial revascularization
and found no difference in renal markers of renal injury
among the groups.
CPB perfusion temperature strategies and their effects on
organ function are largely the result of work carried out in
adult humans, and the conclusions drawn from these studies
cannot necessarily be applied directly to infants or children.
Recently, Durandy and Hulin23 provided an extensive retro-
spective clinical review of their experience with warm CPB
in pediatric cardiac surgery. They comparedmore than 2000
patients who underwent cardiac surgery using either warm
or cold CPB, concluding that normothermia was associated
with improved early outcomes in pediatric patients without
any adverse events. This study, however, was limited by its
retrospective design, and they did not specifically analyze
renal injury. These data, combined with our previously re-
ported evidence on inflammatory response and myocardial
injury,9 confirm the hypothesis that normothermic CPB is
not responsible for any greater deleterious effects on renal
function than hypothermic CPB in a ‘‘low-risk’’ patient
population.
Acute kidney injury is still a common complication after
CPB in children, with a reported incidence of approxi-
mately 5% to 20%,24 and is associated with prolonged hos-
pitalization, poor outcomes, and increased mortality.25
There is growing interest in the use of standardized criteria
to define the occurrence of acute kidney injury in critically
ill children, including those recovering from cardiac sur-
gery.26 In our study population of low-risk patients, 2 pa-
tients, 1 in each group, had mild acute kidney injury
develop, as defined by a 50% or greater increase in serum
creatinine from baseline.
The importance of acute kidney injury combined with the
limited evidence in support of the ideal CPB temperature
during correction of a congenital heart defect in pediatric
surgery makes the need for adequately sized randomized
trials using clinical outcomes as primary end points even
more urgent. In this study on relatively low-risk patients,
normothermic CPB has been shown to be as safe as hypo-
thermic CPB in terms of renal damage. It is not possible,
at the moment, to generalize these findings to higher-risk
patients (neonates or infants with longer CPB and ischemic
times). Nevertheless, at our institution we are conducting
a randomized controlled trial that is enrolling both low-
risk and higher-risk patients (neonates and infants not
requiring hypothermic circulatory arrest) randomizing to
normothermic or hypothermic CPB, with the specific aim
of looking at organ damage and clinical outcomes as pri-
mary end points.The Journal of Thoracic and CarLIMITATIONS
The study was powered to detect changes in biochemical
markers but not in clinical outcome. It excluded neonates
and patients with complex congenital heart diseases who
are more likely to have postoperative renal dysfunction
than patients included in the trial and patients with pre-
existing renal dysfunction, who are at highest risk of post-
operative renal dysfunction. These patient groups stand to
benefit most from a nephroprotective intervention. Also,
we used 3 specific markers of tubular and glomerular injury.
There are other markers available commercially that could
have been used, and the combination of all these markers to-
gether might give us a more comprehensive picture of the
renal damage in these patients.CONCLUSIONS
In infants and children requiring correction of simple
congenital heart defects, normothermic CPB is associated
with similar renal injury compared with hypothermic
CPB. This is the first randomized trial evidence of the im-
pact of normothermic CPB on renal function and contrib-
utes to the accumulating evidence of the safety of this
technique in pediatric heart surgery.
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Dr Richard G. Ohye (Ann Arbor, Mich). Congratulations, Dr
Caputo and colleagues, for completing this trial.
I have 2 questions. As background, I think, the majority of us
either do use or would feel very comfortable using normothermia
in these straightforward operations with short or limited bypass
times. What is the applicability to other cases that are more com-
plex or that have longer bypass times? How may your data be ap-
plicable to neonates and more complex operations?
What was the reason for excluding neonates? Do you think that
there is anything unique in their anatomy or physiology that may
make these data applicable or not applicable?
Similarly, for more complex operations with longer bypass
times, did you look at interactions between with bypass time and1120 The Journal of Thoracic and Cardiovascular Suryour outcomes that may show a greater or lesser effect at longer
bypass times? It is those more complex operations in which these
data may be more applicable.
My second question relates to your graphs, which consistently
show a suggestion of a benefit for normothermia, although not sta-
tistically significant. Are you willing to speculate that normother-
mia might not only be worse, but might be beneficial compared
with moderate hypothermia?
Dr Caputo. The reason we excluded neonates to start with was
that, as in many other units, we were using hypothermia routinely,
and to start the trial, we decided that for neonates wewere not com-
fortable using normothermia.
The trial actually is still ongoing, because the second part of this
trial will look at clinical outcomes, and the sample size for that is
around 300 patients. For that we are excluding only patients who
require hypothermic circulatory arrest. For example, we are now
doing switches with normothermia for sure.
In terms of the effect of CPB time on these markers, we did not
look specifically at the relationship and it is probably worthwhile
doing that.
Dr Ohye. Are you willing to commit that normothermia may
actually be beneficial compared with hypothermia?
Dr Caputo. Personally, I feel much more comfortable with nor-
mothermia, because I really believe that cooling and rewarming
are actually detrimental for several organs, and I think the kidney
is one of them.
Dr Constantine Mavroudis (Cleveland, Ohio). I wonder
about the rate of myocardial rewarming during cardioplegic ar-
rest during normothermic CPB caused by collateral flow or organ
proximity to the heart. Do you plan to use myocardial tempera-
ture measurements in the future? In addition, in retrospect, did
you notice with your normothermic group that the cardioplegia
administration did not last as long as determined by immergence
of electrical activity? Was there evidence of myocardial dysfunc-
tion after the operation? I think most people would use hypother-
mia not only for flow reasons but also to protect against
myocardial rewarming. What are your thoughts about these
issues?
Dr Caputo. Yes, we did look at the heart, and this was actually
published a couple years ago.When we looked at markers of ische-
mia–reperfusion injury and reoxygenation injury in these 2 groups,
we noticed that the normothermic group had less, for example, tro-
ponin I or 8–isoprostane release. Again, we do not believe that
there are detrimental effects on the heart. On the contrary, in terms
of reoxygenation injury, we might believe that normothermic CPB
was beneficial.
In the same study we did evaluate the inflammatory response
of the 2 techniques, and there was no difference. I am pretty con-
fident that normothermia is safe for the heart. In fact, there is
now evidence from groups in Paris using warm plegia, even
though these are retrospective analyses, but they achieve quite
good outcomes.
Dr Tara Karamlou (Seattle, Wash). I have 2 quick questions:
First, can you briefly talk about your protocol regarding ultrafiltra-
tion? Did you use modified ultrafiltration in both groups equally? I
wonder whether some of the markers that you are measuring could
be affected by the use of modified ultrafiltration, especially in the
short term.gery c November 2011
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is not just a statistical type II error, since you found no difference in
many of your outcome measures?
Dr Caputo.We did not use modified ultrafiltration in these pa-
tients because they were not neonates. Normally we tend to use
modified ultrafiltration in patients weighing below 5 kg, so they
did not receive ultrafiltration. Also, we measured the hematocrit
of all these patients.
Dr Karamlou. Thus even if you were not using modified ultra-
filtration, what was the perfusion strategy in terms of using filtra-
tion during the bypass times?
DrCaputo.These patients specifically were not subjected to fil-
tration during bypass, and the hematocrit was the same at all the
time points for the 2 groups. We did measure the hematocrit levels.
Also, the renal function was actually in the urine, so the main
markers are expression of the glomerular damage and tubular dam-
age in the urine according to the glomerular filtration rate. That is
the reason we looked at the ratio between the markers and the cre-
atinine in the urine.
Please remind me of the second question.
Dr Karamlou. The second question was about power.
Dr Caputo. Yes, the power for these markers was based on our
previous experience, and the sample size calculation was done on
the area under the curve of these markers previously measured inThe Journal of Thoracic and Carsimilar studies. Thirty patients for each group was power enough
to detect a difference there.
Dr Mark H. D. Danton (Glasgow, United Kingdom). Did you
have any patients whowere cyanotic in this group? One could con-
sider that if there were cyanotic patients with hypothermia, the col-
lateral flow may be increased as the systemic vasoconstriction
takes place with hypothermia. Therefore, you may have a differ-
ence, you may have better perfusion to the kidneys and the end or-
gans with normothermic bypass with cyanotic patients.
Dr Caputo. Yes, this is possible. Unfortunately, in this series,
there are very few cyanotic patients. The reason is that this was
clashing with another trial in which we were particularly studying
cyanotic patients and reoxygenation injuries. So unfortunately, I
cannot answer that question, but it is something we will look at
in the future, specifically targeting cyanotic patients.
Dr Emile A. Bacha (New York, NY).What was the temperature
of your cardioplegia?
DrCaputo. It was cold blood cardioplegia in this series, so 4C.
Dr Bacha. At 4C?
Dr Caputo. Yes, standard.
Dr Bacha. What kind of flows were you running?
Dr Caputo. These patients were at 2.5 L.
Dr Bacha. I assume the same flows in both groups.
Dr Caputo. Yes.diovascular Surgery c Volume 142, Number 5 1121
APPENDIX E1. Additional biochemical markers
Hypothermic CPB (n ¼ 31) Normothermic CPB (n ¼ 28) Difference
(normothermichypothermic) P valueMean SE Mean SE
Phosphate (mmol/L)
Baseline (mean, SD) 1.49 0.39 1.49 0.37
Post-op 1.44 0.06 1.38 0.06 0.07 (0.09 to 0.23) .42
Calcium (mmol/L)
Baseline (mean, SD) 2.34 0.13 2.34 0.13
Post-op 2.34 0.02 2.33 0.02 0.01 (0.04 to 0.06) .73
Magnesium (mmol/L)
Baseline (mean, SD) 1.07 0.23 1.09 0.20
Post-op 0.85 0.02 0.85 0.01 0.003 (0.04 to 0.03) .86
Glucose (mmol/L)
Baseline (mean, SD) 4.88 1.04 4.66 0.67
Cross-clamp removal 6.64 0.27 5.58 0.29 1.06
Crossclamp removalþ30 min 7.23 0.27 6.33 0.29 0.89
Crossclamp removalþ2 h 7.28 0.37 6.88 0.39 0.40
Crossclamp removalþ6 h 7.64 0.35 7.29 0.37 0.35
Crossclamp removalþ24 h 6.20 0.26 6.26 0.25 þ0.06
Test for interaction between treatment and time .20
Overall treatment effect 0.53 (1.10 to 0.04) .07
Hematocrit (%)
Baseline (mean, SD) 35.6 5.35 35.9 4.69
Crossclamp removal 26.6 0.44 25.5 0.46 1.09
Crossclamp removalþ30 min 29.5 0.62 29.3 0.66 0.15
Crossclamp removalþ6hrs 33.9 0.78 33.0 0.82 0.94
Cross-clamp removalþ24 h 33.2 0.79 32.8 0.77 0.45
Test for interaction between treatment and time .47
Overall treatment effect 0.66 (1.93 to 0.61) .30
Lactate (mmol/L)
Baseline (mean, SD) 0.98 0.32 1.05 0.41
Crossclamp removal 0.96 0.06 0.97 0.06 þ0.01
Crossclamp removalþ30 min 1.11 0.06 1.10 0.06 0.01
Cross-clamp removalþ2 h 1.06 0.10 1.31 0.11 þ0.25
Crossclamp removalþ6 h 1.24 0.11 1.28 0.12 þ0.04
Crossclamp removalþ24 h 1.03 0.09 1.21 0.10 þ0.18
Test for interaction between treatment and time .25
Overall treatment effect þ0.094 (0.06 to 0.25) .23
Serum creatinine (mmol/L)
Baseline (mean, SD) 58.2 11.9 60.7 11.4
End of CPB 60.0 2.35 57.3 2.39 2.74
End of CPBþ24 h 62.9 2.37 58.3 2.38 4.56
End of CPBþ48 h 61.2 2.33 59.2 2.44 2.03
End of CPBþ72 h 61.9 2.67 62.8 2.88 0.93
Test for interaction between treatment and time .46
Overall treatment effect 2.10 (6.51 to 2.31) .34
Urea (mmol/L)
Baseline (mean, SD) 4.62 1.27 4.55 1.38
End of CPB 4.59 0.21 4.53 0.21 0.05
End of CPBþ24 h 5.73 0.30 5.42 0.30 0.31
End of CPBþ48 h 6.08 0.28 5.05 0.31 1.03
End of CPBþ72 h 5.45 0.29 5.16 0.34 0.28
Test for interaction between treatment and time .18
Overall treatment effect 0.42 (0.88 to 0.04) .072
Sodium (mmol/L)
Baseline (mean, SD) 137.6 1.87 137.7 2.05
End of CPB 139.7 0.47 139.1 0.46 0.60
(Continued)
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APPENDIX E1. Continued
Hypothermic CPB (n ¼ 31) Normothermic CPB (n ¼ 28) Difference
(normothermichypothermic) P valueMean SE Mean SE
End of CPBþ24 h 138.3 0.61 137.5 0.64 0.80
End of CPBþ48 h 136.1 0.61 135.8 0.66 0.28
End of CPBþ72 h 135.6 0.60 134.8 0.70 0.78
Test for interaction between treatment and time .91
Overall treatment effect 0.61 (1.87 to 0.64) .33
Potassium (mmol/L)
Baseline (mean, SD) 4.04 0.30 3.98 0.17
End of CPB 4.21 0.07 4.13 0.07 0.08
End of CPBþ24 h 4.33 0.11 4.19 0.11 0.14
End of CPBþ48 h 4.04 0.09 3.96 0.01 0.08
End of CPBþ72 h 3.94 0.13 3.64 0.16 0.31
Test for interaction between treatment and time .67
Overall treatment effect 0.15 (0.33 to 0.03) .096
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